Professional Documents
Culture Documents
Thesis Submitted to
Jawaharlal Nehru Technological University, Kakinada
MASTER OF PHARMACY
in
INDUSTRIAL PHARMACY
By
KATTAMURI THULASI BHAVANI
B.Pharm
[Reg. No. 14CD1S0906]
14CD1S0906 hereby declare that the Research work entitled DESIGN AND
Guide). The work embodied in this thesis is original and has not been submitted in part
Place:
This thesis is the end of my journey in obtaining my Master of Pharmacy. This thesis
has been kept on track and been seen through to completion with the support and
encouragement of numerous people including my well wishers, my friends, and
various institutions. At the end of my thesis, it is a pleasant task to express my thanks
to all those who contributed in many ways to the success of this study and made it an
unforgettable experience for me.
My Sincere thanks to our college principal, Dr. J.N.Suresh Kumar, M.Pharm, Ph.D.
for his extreme support throughout my journey. Without his support this project work
could not be possible.
I would like to pay high regards to My Parents and My Brother for their
sincerely encouragement and inspiration throughout my research work and lifiting me
uphill this phase on life. I owe everything to them.
1. INTRODUCTION 01-17
3. PLAN OF WORK 20
8. REFERENCES 64-67
LIST OF FIGURES
ER Extended Release
SR Sustained Release
CR Controlled Release
IP Indian Pharmacopoeia
BP British Pharmacopoeia
UV Ultraviolet Spectroscopy
BD Bulk Density
TD Tapped Density
INTRODUCTION
INTRODUCTION
The oral route for drug delivery is the most popular, desirable, and most preferred method for
administrating therapeutically agents for systemic effects because it is a natural, convenient, and cost
effective to manufacturing process. Oral route is the most commonly used route for drug administration.
Although different routes of administration are used for the delivery of drugs, oral route remains the
preferred mode. Even for sustained release systems the oral route of administration has been investigated
the most because of flexibility in designing dosage forms. From many decades, conventional dosage
forms, which are of prompt releasing nature, are used for treatment of acute and chronic diseases. The
conventional dosage forms provide no control over release of drug. To maintain the drug concentration
within the therapeutically effective range, it is often necessary to take these types of conventional dosage
forms several times a day. This results in significant fluctuations in drug levels1. Recently, several
technical advancements have been made. These have resulted in the development of new techniques in
drug delivery. These techniques are capable of controlling the rate of drug delivery, sustaining the
duration of therapeutic activity and/or targeting the delivery of drug to a tissue. The role of drug delivery
today is to take a therapeutically effective molecule with suboptimal physicochemical and/or
physiological properties and develop an optimized product that will still be therapeutically effective but
with added benefits. This is accomplished using the concepts of bioavailability enhancement and
controlled release. Incorporating an existing drug into a new drug delivery system can significantly
improve its performance in terms of efficacy, safety, and improved patient compliance2,3.
Table No: 1 Advantages of controlled release dosage forms over conventional forms.
Advantage Explanation
Reduction in drug blood By controlling the rate of drug release, peaks and
level fluctuation valleys of drug blood levels are eliminated
Reduction in adverse side Because there are fewer drug blood level peaks
effects outside of the drugs therapeutic range and into the
toxic range, adverse side effects occur less
frequently.
It is advantageous to deliver some drugs with short half- life and which are to be given frequently for chronic
ailments, in the form of controlled release formulations. The majority of existing oral controlled release systems
are matrix based, and their principle drug release mechanism is based on drug diffusion through the matrix
system. The diffusion is altered by the pH of the medium, the presence of food, hydrodynamic conditions, and
the bodys other physiological factors, all of which can cause difficulty in controlling the drug release rate and
result in poor in vivo - in vitro correlations (IVIVC) 4. Another delivery method used is the osmotic drug
delivery system, which utilizes the principle of osmotic pressure for the controlled delivery of active agent. The
release rate of drug from these systems is independent of the physiological factors of the gastrointestinal tract to
a large extent. Osmotic systems have a high degree of IVIVC, because of the factors that are responsible for
causing differences in release profiles in in vivo and in vitro (e.g variable pH, agitation) affect the systems to a
much lesser extent5,6.
Out of existing oral controlled release systems, elementary osmotic pump, push pull osmotic pump, and
controlled porosity osmotic pump are the key systems. The controlled-porosity osmotic pump tablet is a spray-
coated or coated tablet with semi permeable membrane (SPM) containing leach able pore forming agents. They
do not have any aperture to release the drugs; drug release is achieved through the pores, which are formed in
the semipermeable wall in situ during the operation. In this system, the drug, after dissolution inside the core, is
released from the osmotic pump tablet by hydrostatic pressure and diffusion through pore screened by the
dissolution of pore formers incorporated in the membrane. The hydrostatic pressure is created either by an
osmotic agent or by the drug itself or by a tablet component, after water is imbibed across the semipermeable
membrane. The release rate from these types of systems is dependent on the coating thickness, level of leach
able components in the coating, solubility of the drug in the tablet core, and osmotic pressure difference across
the membrane but is independent of the pH and agitation of the release media7.
1.1 SOLID ORAL DOSAGE FORMS
Drugs can be administered through different routes, however of all the routes of administration, oral route of
administration is most convenient for administratingdrugs for systemic effect because of ease of administration
by manufacturing and dosage administration8.
Oral route of drug administration has wide acceptable and of the drugs administered orally in solid dosage forms
represents the preferred class of products. Solid dosage forms of tablets and capsules are more commonly
employed, the tablets have advantage than capsules in that they are tamper resistant and any adulterate of tablets
after its manufacture is about certain to be observed9.
Based on the duration of drug release solid orals are classified as
Conventional release (Immediate release)
Modified release dosage forms
Different terminology used in modified release dosage forms:
1. Extended Release Dosage Forms:
A dosage form that allows at least a two fold reduction in dose frequency as compared to the drug presented as
an immediate release10.
Example: controlled release, sustained release.
a. Sustained Release: It includes any drug delivery system that achieves slow release of drugs over an extended
of time not particularly at pre-determined rate.
b. Controlled Release: It includes any drug delivery system from which the drug is delivered at a
predetermined rate over long period.
Fig.1 Plasma drug concentration profiles for conventional tablet or capsule formulation (---) and a zero
order controlled release formulation ( ---).
MEC = Minimum Effective Concentration; MSC = Maximum Safe Concentration
5. Prolonged action dosage forms:
It is designed to release the drug slowly and to provide a continuous supply of drug over an extended period.
Extended release dosage forms are formulated in such a manner as to make the contained drug available over an
extended period of time following administration. Expressions such as controlled release, prolonged action,
repeat action, and sustained action have been used to describe such dosage forms. A typical controlled release
systems is designed to provide constant or nearly constant drug levels in plasma with, reduced fluctuations via
slow release over an extended period of time. More common methods that are used to achieve modified release
of orally administered drugs are as follows12.
Osmosis is the phenomenon that makes controlled drug delivery a reality. Osmotic pressure created due to
imbibitions of fluid from external environment regulates the delivery of drug from the osmotic device. There are
various factors that govern a particular pattern of drug delivery like nature of semipermiable membrane,
diameter of delivery orifice, surface area of semipermeable. Membrane, pH, and electrolyte concentration in
external fluid, nature and concentration of osmogen etc15.
Advantages of ODDS:
Osmotic drug delivery systems for oral and parenteral use offer distinct and practical advantages over other
means of delivery. The following advantages have contributed to the popularity of osmotic drug delivery
systems
The delivery rate of zero- order (which is most desirable) is achieved with osmotic systems. Both in
vitro and in vivo experiments have established this fact.
Delivery may be delayed of pulsed, if desired.
For oral osmotic systems, drug release is independent of gastric pH and hydrodynamic conditions.
Higher release rates are possible with osmotic systems compared with conventional diffusion controlled
released drug delivery systems
The release rate of osmotic systems is highly predictable and can bepreprogrammed by modulating the
release control parameter.
A high degree of IVIVC is obtained in osmotic system.
The release from osmotic systems is minimally affected by the presence of food in the gastrointestinal
tract (GIT)16.
These advantages are attributed to the design of osmotic systems Environmental contents (e.g. GIT
fluids) do not gain access to the drug until the drug has been delivered out of the device.
. Osmotic systems have high degree of IVIVC, because the factors that are responsible for causing
differences in release profiles in in- vivo and in vitro (e.g. variable pH, agitation) affect these systems to
a much lesser extent17.
Classification of osmotic drug delivery system:
Many forms of osmotic pumps are reported in the literature but, in general they can be divided in oral and
implantable systems18. Osmotic Drug Delivery Devices fall in two categories
I. Implantable:
(c) Higuchi- Theeuwes pump: In the early 1973 Higuchi Theeuwes developed a similar form of Rose Nelson
pump as shown the figure. The semi permeable wall itself acts as a rigid outer casing of the pump. The device is
loaded with drug prior to use. When the device is put in an aqueous environment the release of the drug follows
a time course set by the salt used in the salt chamber and the permeability of the outer membrane casing 21.
Basic component of controlled porosity osmotic pump
1. Drug:
Basic criteria for selection of drug
i. It should have short biological half-life and which is used for prolonged treatment are ideal candidate for
osmotic systems.
ii. It should be water soluble.
iii. It should be potent.
2 Osmotic agent:
Osmogens are essential ingredient of the osmotic formulations. Upon penetration of biological fluid into the
osmotic pump through semipermeable membrane, osmogensare dissolved in the biological fluid, which creates
osmotic pressure buildup inside the pump and pushes medicament outside the pump through delivery orifice.
They include inorganic salts and carbohydrates. Mostly, potassium chloride, sodium chloride, and mannitol used
as osmogens. Generally combinations of osmogens are used to achieve optimum osmotic pressure inside the
system Eg: Water-soluble salts of inorganic acids: Magnesium chloride or sulfate; lithium, sodium, or potassium
chloride; lithium, sodium, or potassium sulfate; sodium or potassium hydrogen phosphate, etc
Eg: Water soluble salts of organic acids : Sodium and potassium acetate, magnesium succinate, sodium
benzoate, sodium citrate, sodium ascorbate, etc.
Eg: Carbohydrates: Arabinose, ribose, xylose, glucose, fructose, galactose, mannose, sucrose, maltose, lactose,
raffinose, etc.Water soluble amino acids: Glycine, leucine, alanine, methionine, etc. Organic polymeric
osmogents Sodium carboxy nmethylcellulose, HPMC, hydroxyethyl methylcellulose, cross-linked PVP,
polyethylene oxide, carbopols,polyacrylamides, etc.
3 Hydrophilic and Hydrophobic Polymers:
These polymers are used in the formulation development of osmotic systems for nmmaking drug containing
matrix core. The highly water soluble compounds can be coentrapped in hydrophobic matrices and moderately
water soluble compounds can be coentrapped in hydrophilic matrices to obtain more controlled release.
Generally, mixtures of both hydrophilic and hydrophobic polymers have been used in the development of
osmotic pumps of water-soluble drugs . The selection is based on the solubility of the drug as well as the
amount and rate of drug to be released from the pump. Ionic hydrogels such as sodium carboxymethyl cellulose
are preferably used because of their osmogenic nature. More precise controlled release of drugs can be achieved
by incorporating these polymers into the formulations. Examples: hydroxy ethyl cellulose, carboxy
methylcellulose, hydroxy propyl methylcellulose, high-molecular-weight poly (vinyl pyrrolidone), and
hydrophobic polymers such as ethyl cellulose and wax materials can be used for this purpose.
4 Coating solvents:
Solvents suitable for making polymeric solution that is used for manufacturing the wall of the osmotic device
include inert inorganic and organic solvents that do not adversely harm the core and other materials. The typical
solvents include methylene chloride, acetone, methanol, ethanol, isopropyl alcohol, butyl alcohol, ethyl acetate,
cyclohexane, carbon tetrachloride, and water. The mixtures of solvents such as acetone-methanol (80 : 20),
acetone-ethanol (80 : 20), acetone-water (90 : 10), methylene chloride-methanol (79 : 21), methylene chloride-
methanol-water (75 : 22 : 3) can be used.
5 Plasticizers:
In pharmaceutical coatings, plasticizers, or low molecular weight diluents are added to modify the physical
properties and improve film-forming characteristics of polymers. Plasticizers can change visco elastic behavior
of polymers significantly . Plasticizers can turn a hard and brittle polymer into a softer, more pliable material,
and possibly make it more resistant to mechanical stress. Plasticizers lower the temperature of the second order-
phase transition of the wall or the elastic modules of the wall and also increase the workability, flexibility, and
permeability of the coating solvents. Generally from 0.001 to 50 parts of a plasticizer or a mixture of plasticizers
are incorporated into 100 parts of costing materials. PEG-600, PEG-200, triacetin (TA), dibutyl sebacate,
ethylene glycol monoacetate, ethylene glycol diacetate, triethyl phosphate, and diethyl tartrate used as
plasticizer in formulation of semipermeable membrane.
6. Semipermeable membrane:
Any polymer that is permeable to water but impermeable to solute can be used as a coating material in osmotic
devices Since the membrane in osmotic systems is semipermeable in nature, any polymer that is permeable to
water but impermeable to solute can be selected . Cellulose acetate is a commonly employed semipermeable
polymer for the preparation of osmotic pumps. It is available in different acetyl content grades. Particularly,
acetyl content of 32% and 38% is widely used. Acetyl content is described by the degree of substitution (DS),
that is, the average number of hydroxyl groups on the anhydro glucose unit of the polymer replaced by
substituting group e.g. Cellulose esters like cellulose acetate, cellulose acetate butyrate, cellulose triacetate and
ethyl cellulose and Eudragits. Some other polymers such as agar acetate, amylose triacetate, betaglucan acetate,
poly (vinylmethyl) ether copolymers, poly (orthoesters), poly acetals, poly (glycolic acid) and poly (lactic acid)
derivatives.
Ideal properties of semipermeable membrane:
1. It should be stable to both outside and inside environments of the device.
2. It must be .sufficiently rigid so as to retain its dimensional integrity during the operational lifetime of the
device.
3. It should be relatively impermeable to the contents of dispenser so that osmogent is not lost by diffusion
across the membrane.
4. The membrane must be biocompatible.
5. The material must possess sufficient wet strength (10-5 Psi) and wet modules so (10-5 Psi) as to retain its
dimensional integrity during the operational lifetime of the device.
6. The membrane must exhibit sufficient water permeability so as to attain water flux rates (dv/dt) in the desired
range. The water vapour transmission rates can be used to estimate water flux rates.
7. The reflection coefficient or leakiness of theosmotic agents should approach the limiting value of unity. But
polymer membranes must be more permeable to water.
7. Channeling agents or pore forming agents:
These are the water-soluble components which play an important role in the controlled drug delivery systems.
When the dissolution medium comes into contact with the semipermeable membrane it dissolves the channeling
agent and forms pores on the semipermeable barrier. Then the dissolution fluid enters the osmotic system and
releases the drug in a controlled manner over a long period of time by the process of osmosis.
Example of pore forming agent- sodium chloride, sodium bromide, potassium chloride, calcium chloride
calcium nitrate, glucose, fructosemannose, Diethylphthalate, Dibutylphthalate, Dibutylsebacate etc.
Factors affecting the release of drug through controlled porosity osmotic pump:
Drug: Osmotic agent ratio
As concentration of osmotic agent in the tablet core has increases the rate of drug release is also increases. It is
due to the increase in osmotic pressure on increasing the concentration of osmotic agent. As different osmotic
agent posses the different osmotic pressure the release of drug trough drug delivery system is depend on the
type of osmotic agent.
Level of coating thickness
Drug release from the system is inversely proportional to the level of coating thickness. As thickness of coating
increases the drug release decreases.
Porosity of coating membrane
As porosity of coating membrane get increases the rate of drug release is increases. The porosity of coating
membrane is depend on the type and concentration of channeling agent.
1.3 DIABETES MELLITUS:
Simply diabetes is a group of metabolic diseases in which a person has high blood sugar, either because the
pancreas does not produce enough insulin, or because cells do not respond to the insulin that is produced. This
high blood sugar produces the classical symptoms of polyuria (frequent urination), polydipsia (increased thirst)
and polyphagia (increased hunger) 22.
PLAN OF WORK
It was planned to carryout study in the sequences below,
Angle of repose
Bulk density
Tapped density
Compressibility index/ Carrs index
Hausners ratio
4. Evaluation of post compression characteristics of Glipizide osmotic pump drug
release tablets.
Hardness
Friability
Weight variation
Thickness
% Drug content/content uniformity
In-vitro release study/dissolution
5. Selection of best formulation on the basis of in- vitro drug release.
6. Determining the order of drug release from matrix tablets and mechanism of drug
release.
7. Comparison of Best Formulation with Marketed product.
8. Stability studies of optimised formulation.
LITERATURE SURVEY
Kambham venkateshwarlu et al., Matrix tablets of Glipizide with combination of hydrophobic
polymers Eudragit RL100 (Powder form) and Ethyl cellulose were developed by direct compression
method. In this formulation the effect of polymer concentration on drug release was studied. As the
concentration of Ethyl cellulose increased drug release decreased and when the MCC concentration
increased drug release increased24.
Anil Chaudhary et al., Micro porous bilayer osmotic tablet for colonspecific delivery. Micro
porous bilayer osmotic tablet bearing dicyclomine hydrochloride and diclofenac potassium was
developed using a new oral drug delivery system for colon targeting. The tablets were coated with
microporous semi permeable membrane and enteric polymer using conventional pan-coating
process. In vitro dissolution results indicated that system showed acid-resistant, timed release and
was able to deliver drug at an approximate zero order up to 24 h. The developed tablets could be
effectively used for colon-specific drug delivery to treat Irritating bowel syndrome25.
Vamshi Krishna Lekkala et al., Developed Elementary Osmotic Pump (EOP) tablets of metformin
Hcl. Linear and reproducible release similar to that of Fortamet ER 1000 mg tablets was achieved
for optimized formulation (f2 >50) independent of hydrodynamic conditions. The effect of different
formulation variables, namely, ratio of drug to osmogen, membrane weight gain, and level of pore
former on the in vitro release was studied. The drug release by Metformin Hcl ER tablets by osmotic
technology is around 85% in 20 hrs. The optimized formulations were subjected to stability studies
as per International Conference on Harmonization (ICH) guidelines and formulations were stable
after a 3 month study26.
R. Kumaravelrajana et al., Simultaneous delivery of Nifedipine and Metoprolol tartarate using
sandwiched osmotic pump tablet system. It is developed in order to reduce the problems associated
with multidrug therapy of hypertension. This system composed of a middle push layer and attached
drug layers of Nifedipine and Metoprolol. The tablets are prepared by wet granulation technique.
Polyethylene oxide 600,000 and 8,000,000 g/mole were used as thickening agent of drug layer and
the expandable hydrogel of push layer, respectively. It has been observed that amount of
polyethylene oxide (PEO) and KCL of the drug and push layer had profound influence on Nifedipine
and Metoprolol release. Further, the release of drugs was optimized by the size of the delivery
orifice, level of plasticizer and membrane thickness. The optimal osmotic pump tablet was found to
deliver both drugs at a rate of approximately zero order for up to 16 h independent of pH and
agitational intensity, but dependent on the osmotic pressure of the release media. Further sandwiched
system had a good sustained effect in comparison with the conventional product. Hence the
prototype design of the system could be applied to other combinations of drugs used for
cardiovascular diseases, diabetes27.
Ritesh B. Patel et al., Developed osmotic pump tablets (OPT) of glipizide (GLZ) and optimized the
formulation using response surface methodology. The complex of GLZ and HP--CD were prepared
and studied the effects of different ratio of drug to HP--CD and preparation methods on complex
formation. The effects of the osmogen, diameter of the drug releasing orifice, and coating
composition on the drug release profile were investigated during the preliminary trials. Response
surface methodology was used to optimize the OPT. In-vitro drug release profiles from osmotic
tablet were compared with theoretical release profile and statistically analyzed to examine suitability
of OPT for once a day administration. Complex prepared using solvent evaporation method in ratio
of 2:1 showed good solubility and dissolution enhancement. The release from the optimized
formulations was independent of pH and agitation intensity of the release media, assuring the release
to be fairly independent of pH and hydrodynamic conditions of the body. The drug release from OPT
with the optimized formulation showed a controlled release pattern28.
N.G.Raghvendra Rao et al., Prepared controlled zero order release glipizide bilayer matrix tablets
using HPMC, Xanthan gum ,Guar gum ,Karaya gum. Effect of polymer concentration and polymer
blend were studied. It was observed that tablets containing polymer blend of HPMC-Ethyl cellulose
were successfully sustained the drug release up to 12 hours29.
Longxiao L et al., developed a bilayer-core osmotic pump tablet (OPT) which does not require laser
drilling to form the drug delivery orifice is described. The bilayer-core consisted of two layers: (a)
push layer and (b) drug layer, and was made with a modified upper tablet punch, which produced an
indentation at the center of the drug layer surface. Nifedipine was selected as the model drug. The
indented core tablet was coated by ethyl cellulose as semipermeable membrane containing
polyethylene glycol 400 for controlling the membrane permeability. It was found the optimal OPT
was able to deliver nifedipine at an approximate zero-order up to 24 hrs, independent on both release
media and agitation rates. The preparation of bilayer core OPT was simplified by coating the
indented core tablet, by which sophisticated technology of the drug layer identification and laser
drilling could be eliminated30.
Shokri J. et al., Developed a new type of elementary osmotic pump (EOP) tablet for efficient
delivery o f poorly water-soluble/practically insoluble drugs. Drug release from the system, called
DEPATRMENT OF INDUSTRIAL PHARMACY, NIPS Page 22
LITERATURE SURVEY
swellable elementary osmotic pump (SEOP), I through a delivery orifice in the form of a very fine
dispersion ready for dissolution and absorption. The release behavior of indomethacin from different
formulations of this dosage form was studied at pH 6.8 for a period of 24 h. The formulations were
compared based on four comparative parameters, namely, D24h (total release after 24 h), tL (lag
time), RSQ zero (R square of zero order equation) and D% zero (percentage deviation from zero
order kinetics). The results showed that concentration of wetting agent in the core formulation was a
very important parameter in D24h and release pattern of indomethacin from SEOP system.
Increasing the amount of wetting agent to an optimum level (60 mg) significantly increased D24h
and improved zero order release pattern of indomethacin. Increasing concentration of castor oil
(hydrophobic) in the semipermeable membrane of the device or hydrophilic plasticizer (glycerin) in
diameter for the formulations studied here was determined to be 650 m for zero order release
pattern. tL and D% zero were dramatically decreased whereas D24h and RSQ zero increased with
increasing the aperture size to optimum level31.
Reza fassihi et al., Prepared monolithic matrix system of glipizide tablets by using the swellable
hydroxypropylmethylcellulose (HPMC) or erodible polyethylene oxide (PEO). In this study linear
release of glipizide, similar to the profile of the commercial PPOP system, Glucotrol XL. The
interrelationship between matrix hydration, erosion and textural properties were determined and
analyzed under the dissolution test conditions. HPMC matrices showed a significantly greater degree
of hydration and swelling and stronger texture property relative to PEO matrices. Resultsindicate that
in the case of low dose/low soluble drug, total drug release in a zero order manner heavily depends
on the synchronization of erosion and swelling fronts during the entire dissolution study32.
Vincent Malaterre et al., Prepared a simple elementary osmotic pump (EOP)system that could
deliver metformin hydrochloride (MT) and glipizide (GZ) simultaneously for extended periods of
time was developed in order to reduce the problems associated with multidrug therapy of type 2 non-
insulin-dependent diabetes mellitus. Good sustained effect in comparison with the conventional
product. The prototype design of the system could be applied to other combinations of drugs used for
cardiovascular diseases, diabetes, etc33.
Suresh P. Vyas et al., studied an oral osmotic system which can deliver theophylline and
Salbutamol sulphate simultaneously for extended period of time. A modified two layered, pushpull
osmotic system was developed by using the basic designs of various oral osmotic pumps, such as
controlled porosity osmotic pump (CPOP), elementary osmotic pump (EOP) and pushpull osmotic
pump (PPOP). Cellulose acetate solution with 25% (w/w) of sorbitol can be used as an optimized
concentration of pore forming agent with 25% (w/w) of plasticizer, which was keep constant34.
Thombre AG et al., studied a controlled porosity osmotic pump-based drug delivery system.
Pseudoephedrine was chosen as a model drug with an aim to develop a controlled release system for
a period of 12 h. Sodium bicarbonate was used as the osmogen. The effect of different ratios of drug:
osmogen on the in-vitro release was studied. Cellulose acetate (CA) was used as the semipermeable
membrane. Different channeling agents tried was diethyl phthalate (DEP), dibutylphthalate (DBP)
dibutylsebacate (DBS) and polyethylene glycol 400 (PEG 400). It was found tha drug release rate
increased with the amount of osmogen due to the increased water uptake and hence increased driving
force for drug release. This could be retarded by the proper choice of channeling agent in order to
achieve the desired zero order 35.
9 Potassium di hydrogen
Hetero labs Ltd., Jedcherla
10 Phosphate
Sodium hydroxide Hetero labs Ltd., Jedcherla
DRUG PROFILE36
Drug name: Glipizide
Chemical Name: 1-cyclohexyl-3-[[p-[2-(5-ethylpyrazinecarboxamido) ethyl] phenyl]
sulfonyl] urea
Chemical formula: C21H27O5S4
Molecular Weight: 445.54
Chemical structure:
daily dosing of Glipizide sustain release, effective plasma concentrations are maintained throughout
24 hours period with fewer peaks to trough fluctuations. In view of the time required to reach an
optimal concentration in plasma, drug may be more effective when given 30 minutes before eating.
Drug in plasma 98.3% bound to plasma protein especially with albumin. Drug is metabolized in
liver, and the metabolites are excreted in urine. Less than 5 % drug excreted unchanged in urine.
Pharmacokinetics:
Glipizide is completed and rapidly absorbed ensuring prompt and constant activity Peak plasma
concentrations are attained within 1.5-2.0 hours after a single oral dose. The half-life of elimination
ranges from 2 to 3 hours. The drug is excreted in the urine as virtually inactive metabolites. When
taken before each meal, glynase controls postprandial hyperglycemia without the risk of delayed
episodes of hypoglycaemial. Dependent Diabetes Mellitus where diet control alone is not effective in
controlling the hyperglycemia. Dosage should be adapted to patients individually, on basis of
periodic tests of glycosuria and blood sugar. The maximum daily dose should not exceed 10 mg.
Contraindication:
Like other sulfonylureas, Glipizide is contraindicated in: Insulin dependent diabetes mellitus,
diabetic-keto-acidosis, diabetic coma, pregnancy, subjects with severel impaired kidney or liver
function, adrenal insufficiency and cases of confirme individual hypersensitivity to the drug. In latent
diabetes or prediabetic states, the use of sulfonylurea is not advisable.
Interaction:
The hypoglycemic actions of sulfonylurea may be potentiated by certain drugs including
nonsteriodal anti-inflammatory drugs and other drugs that are highly protein bound salicylates,
sulphonamides, and chlormphenicol. When such drugs are administered to a patient receiving
Glipizide, the patient should be observed for hypoglycemia.
Side effects:
Hypoglycemia, Gastrointestinal disturbances, allergic reactions including erythema, urticaria.
Precaution:
Patients should be instructed to closely follow their physicians prescription as regards diet, dosage
and schedule for taking the drug, and should be taught to recognize promptly the early symptoms of
hypoglycemia, that generally are headache, irritability, sleep disorders, tremor and heavy sweating,
so they can contact a doctor in good time.
No well-defined upper limits reported for therapeutically effective plasma concentration. However,
threshold concentration of 300 ng/ml has been suggested above which no additional glucose-
lowering effect is likely to be achieved.
EXCIPIENT PROFILE37
POLYETHYLENE OXIDE
Synonyms
Polyethylene oxide
Structural Formula
Functional Category
Polyethylene oxide can be used as a tablet binder at concentrations of 585%. The higher molecular
weight grades provide delayed drug release via the hydrophilic matrix . The relationship between
swelling capacity and molecular weight is a good guide when selecting products for use in
immediate- or sustained-release matrix formulations; Polyethylene oxide has been shown to be an
excellent mucoadhesive polymer. Low levels of polyethylene oxide are effective thickeners,
although alcohol is usually added to waterbased formulations to provide improved viscosity stability;
Polyethylene oxide films demonstrate good lubricity when wet. This property has been utilized in the
development of coatings for medical devices. Polyethylene oxide can be radiation crosslinked in
solution to produce a hydrogel that can be used in wound care applications.
Description
CELLULOSE ACETATE :
Synonyms: Acetyl cellulose, cellulose diacetate, cellulose triacetate
Molecular formula: Cellulose acetate is cellulose in which a portion or all of the hydroxyl groups
are acetylated. Cellulose acetate is available in a wide range of acetyl levels and chain lengths and
thus molecular weight.
Description: It occur s as a white to off white powder, free flowing pellets, or flakes. It is tasteless
and odorless or may have a slight odor of acetic acid.
Functional category: Coating agent, extended release agent, tablet and capsule diluents
Applications in pharmaceutical formulation:
It is used as a semi permeable coating on tablets, especially on osmotic pump-type tablets and
implants. This allows for controlled, extended release of actives. Cellulose acetate films, in
conjunction with other materials, also offers sustained release without the necessity of drilling a hole
in the coating as is typical with osmotic pump systems.Cellulose acetate films have also been used in
transdermal drug delivery studies. Also used as a film coating on tablet or granules for taste masking.
Solubility: cellulose acetates are soluble in acetone; water blends o f varying ratios, methylene
chloride, ethanol blends, dimethylformamide, and dioxane.
Stability and storage condition: It is stable if stored in a well closed container in a cool and dry
place. Cellulose acetate hydrolyzes slowly under prolonged adverse conditions such as high
temperature and humidity.
Incompatibilities:It is incompatible with strongly acidic or alkaline substances. Cellulose acetate is
compatible with the following plasticizers: triacetin, triethyl citrate, dimethyl phthalate, and
polyethylene glycol.
Safety: It is widely used in oral pharmaceutical products and it generally regarded as a nontoxic and
nonirritant material.
POLYETHYLENE GLYCOL:
Synonyms: Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogola; PEG;Pluriol E;
polyoxyethylene glycol.
Chemical Name: -Hydro- hydroxypoly(oxy-1,2-ethanediyl).
Molecular Formula: HOCH2(CH2OCH2)mCH2OH where m represents the average number of
oxyethylene groups.
SODIUM CHLORIDE:
Synonyms: Alberger; chlorure de sodium; common salt; hopper salt; natrichloridum; natural halite;
rock salt; saline; salt; sea salt; table salt.
Molecular Formula: NaCl
Molecular Weight: 58.44
Functional Category: Tablet and capsule diluent; tonicity agent.
Description: Sodium chloride occurs as a white crystalline powder or colorless crystals; it has a
saline taste. The crystal lattice is a face centered cubic structure. Solid sodium chloride contains no
water of crystallization although, below 8o C, salt may crystallize as adihydrate.
Applications in Pharmaceutical Technology:
Sodium chloride is widely used in a variety of parenteral and nonparenteral pharmaceutical
formulations, where the primary useis to produce isotonic solutions.Sodium chloride has been used
as a lubricant and diluents in capsules and direct-compression tablet formulations in the
past,although this practice is no longer common. Sodium chloride hasalso been used as a channeling
agent and as an osmotic agentin the cores of controlled-release tablets.
Table No:7 Uses of Sodium chloride
Incompatibilities:
Aqueous sodium chloride solutions are corrosive to iron. They alsoreact to form precipitates with
silver, lead, and mercury salts. Strongoxidizing agents liberate chlorine from acidified solutions of
sodiumchloride. The solubility of the antimicrobial preservative methylparabenis decreased in
aqueous sodium chloride solution andthe viscosity of carbomer gels and solutions of
hydroxyethylcellulose or Hydroxypropyl cellulose is reduced by the addition of sodium chloride.
7 Friabilator Eletrolab(USP)
METHODOLOGY
5.1 ANALYTICAL METHODS38:
1. Preparation of Buffer and Reagent:
Phosphate buffer solution, pH 7.5: 6.8gm of potassium dihydrogen phosphate was placed in a 1000
ml volumetric flask, dissolved with distilled water and the final pH was adjusted with 0.2N sodium
hydroxide solution.
2 Determination of max of the drug: Glipizide was dissolved in pH 7.5 phosphate buffer solution
[PBS] and further diluted with the same and scanned for maximum absorbance in double beam UV-
visible spectrophotometer in the range from 200 to 400 nm, using PBS pH 7.5 as blank. The max of
the drug was found to be at 222 nm.
3.Standard curve of glipizide in phosphate buffer (pH 7.5): 100 mg of Glipizide was accurately
weighed and dissolved in 100 ml of PBS to prepare stock solution. The aliquot amount of stock
solution was further diluted with PBS pH 7.5 to get 2 g/ml, 4 g/ml, 6 g/ml, 8 g/ml, 10 g/ml
and 12 g/ml of the final drug solution. Then the peak area was measured by UV method of analysis
at max 222nm.
5.2 PREFORMULATION STUDIES:
1. Drug Excepients Interaction Studies:
Drug excepients interaction studies were studied by using FTIR spectroscopic studies to study the
interaction studies following combinations were used.
1. Pure Drug
2. Pure Drug with polymers .
Table No: 9 The FTIR spectra of pure drug were observed for peaks at wave Numbers
2 Determination of melting point: Melting point was determined by taking small amount of
Glipizide in a capillary tube closed at one end. The capillary tube was placed in an electrically
operated melting point apparatus and the temperature at which the drug melts was recorded. This
was performed thrice and average value was noted.
3 Saturation solubility of drug in PBS pH 7.5:
Excess of drug (approximately 100 mg) was added in 30 ml of glass vial containing 10 ml of water
and buffer solutions of different pH. All the vial were screw capped tightly and kept for shaking (at
160 rpm) on a shaking water bat at 37 C for 48 h. The samples were kept undisturbed for 12 h at the
same temperature and then filtered through 0.22 micron nylon membrane filter Samples were
analyzed at max 225 nm after suitable dilutions.
5.3 FORMULATION DEVELOPMENT:
Preparation of Glipizide tablets:
Push layer
Drug layer composed of Glipizide, Polyox WSR coagulant and Lactose are weighed accurately and
passed through 40#. The mixed powder was granulated with ethanol. Wet mass dried in Fluidized
bed dryer at 250c, 15 amp airflow for 15 minutes.
Pull layer
Pull layer composed of Sodium chloride, Polyox WSR coagulant 301, Ferric oxide red Fe203 passed
through 60# and mixed properly. The mixed powder was granulated with ethanol. Wet mass dried in
Fluidized bed dryer at 250c, 15 amp airflow for 15 minutes.
After drying two layers are lubricated with magnesium stearate which passed through 60#. Blend it
in a blender for 5 minutes. The prepared blend was placed in die cavity and compressed with
hardness 3.2-4 kp with diameter 3.68 mm by 8 mm round standard concave punches with machine
by bi layer tablet method.
Table No: 10 Formulation table of the Glipizide osmotic controlled release tablets
s.no. Ingredients F1 F2 F3 F4 F5 F6 F7
1 core tablet
Glipizide mg/un
10 mg/unit
10 mg/unit
10 mg/unit
10 mg/unit
10 mg/unit
10 mg/unit
10
Polyox WSR it
coagulant
2 86 86 86 86 86 86 86
3 Ethanol q.s q.s q.s q.s q.s q.s q.s
4 Sodium chloride 30 30 30 50 50 70 70
5 Polyox WSR 70 70 70 50 50 30 30
coagulant 301
6 Ethanol q.s q.s q.s q.s q.s q.s q.s
7 Ferric oxide red 2 2 2 2 2 2 2
Magnesium
8 Stearate 2 2 2 2 2 2 2
core tablet
weight (mg) 200 200 200 200 200 200 200
coating(3% w/w)
Coated tablet
weight (mg)
** 208 208 208 208 208 208
The coating material consist of 3%w/w of the solution, the solution consist cellulose acetate and
polyethylene glycol 400 (in 70:30 and 50:50 ratio), cellulose acetate act as semi permeable
membrane polyethylene glycol 400 act as plasticizer. These materials are dissolved in acetone &
water (in 9:1 ratio). Acetone was taken in a beaker and in kept magnetic stirrer while stirring the
cellulose acetate was added and the stirring was continued for 15min the cellulose acetate was
completely dissolved. The same procedure followed to water &PEG 400 for 15min, PEG 400 was
dissolved in water, above solution was added to cellulose acetate solution and kept for 15min
stirring. While coating the material was wasted for this reason we take 50% extra coating material.
Before applying coating solution, all weighed tablets put in coating pan and pre -warming for 15min
in this time the bed temperature (28-30oC) was maintained and collect the some tablets and
average weight of the tablets was measured. Spray the coating solution on tablets through spray gun
and also supply hot air to dry the tablets. During this procedure coating pan rotated continuously.
This process is continued for required percentage of weight gain up to 12%. After coating the
solution spray was stopped and tablets kept 15min for post warming. Dry tablets are weighed and
the average weight was determined. The % of weight gain was calculated by following equation.
% weigh gain = (Wt-Wo/ Wo) *100
Where,
Wt = weight of tablet after coating
Wo = weight of tablet before coating
Table No: 12 Coating machine (NEO COTA) process parameters and its limits.
The coated tablet drill in depth 0.5 mm and width 0.5 mm to the pull layer of the coated tablet for the
purpose of push and pull layer mechanism.
The coating material consist of 1%w/w of the solution, the solution consist opadry white purified water
as solvent. purified water was taken in a beaker and in kept magnetic stirrer while stirring the opadry
white was added and the stirring was continued for 15min. Before applying coating solution, all weighed
tablets put in coating pan and pre -warming for 15min in this time the bed temperature (28-30oC) was
maintained and collect the some tablets and average weight of the tablets was measured. Spray the
coating solution on tablets through spray gun and also supply hot air to dry the tablets. During this
procedure coating pan rotated continuously. This process is continued for required percentage of weight
gain up to 12%. After coating the solution spray was stopped and tablets kept 15min for post warming.
Dry tablets are weighed and the average weight was determined. The % of weight gain was calculated by
following equation.
Table No: 13 Coating machine (NEO COTA) process parameters and its limits
Bulk Density; An accurately weighed (10gr) quantity of powder was transferred to a 100ml
measuring cylinder and the volume occupied by the powder in terms of ml was recorded.
Weight of powder in gm.
Bulk Density = ---------------------------------
Volume of powder in ml
Tapped bulk Density: The loosely packed powder in the measuring cylinder was tapped by USP
type II apparatus. Initially 500 times tapped and then go for 750 taps. If volume difference is more
than 2% between the 500& 750 taps then go for 1000taps. This procedure continued until the
consecutive difference between the taps is below or equal to 2% and finally measure the powder
volume
TBD - LBD
Tapped bulk density = --------------------- 100
TBD
Hausners ratio: The Hausners ratio of the drug and granules was determined by following equation it
was used to predict powder flow properties.
Hausners ratio = (TBD/LBD)
Angle of Repose: It is measured to find frictional forces in loose powder or granules. It is the
maximum angle possible between the surface of a pile of powder or granules and horizontal plane.
Where,
h = the height of the powder cone
r = the radius of the powder cone
Flow properties for different values of angle of repose are given below
20 tablets were weighed individually and average weight was calculated from the total weight of 20
tablets. The individual weights were compared with the permissible limits (5 %). The percent
deviation was calculated using the following formula
Individual weight average weight
Percentage Deviation = --------------------------------------------- x 100
Average weight
Hardness test: 6 Tablets were randomly selected from each batch and hardness of each tablet was
determined by using a Pharmag instruments.
Friability test: It is the ability of tablets to withstand mechanical shocks during handling and
transportations 6.5gr of tablets were picked from each batch and weighed and placed in the Rochae
friability test apparatus and operated at rate of 25 RPM for 4 minutes (or up to 100
revolutions),tablets were de-dusted and weighed again. The loss of tablet weight due to abrasion and
fracture was measured in terms of % friability (A value of <1%F is acceptable).
Initial wt final wt
F = -------------------------- 100
Initial wt
Drug content estimation: The Glipizide tablets were tested for their drug content. Five tablets were
finely powdered required quantities of the powder equivalent to 10 mg of Glipizide were accurately
weighed and transferred to a 100ml of volumetric flask. The flask was filled with Phosphate buffer
(pH 7.5) solution and mixed thoroughly. The solution was made up to volume and filtered. Dilute 10
ml of the resulting solution to 200 ml with Phosphate buffer (pH 7.5) and measure the absorbance of
the resulting solution at the max 222 nm using a UV spectrophotometer. The linearity equation
obtained from calibration curve as described previously was used for estimation of Glipizide in the
tablet formulations.
In-vitro Dissolution studies:
In vitro drug release studies of the prepared tablets were conducted for a period of 16 hours using an
eight station USP type II apparatus (ELECTROLAB, India) at 370.50C the paddle speed was 50
1 rpm. The dissolution medium used in each flask was 900 ml of buffer media pH 7.5 At different
intervals, 10 ml of samples were withdrawn and filter through a whatman filter paper. The equivalent
volume of the medium was added to the dissolution flask.
Analysis of drug release by UV-Visible spectrophotometer:
The collected samples were filtered and appropriate dilution was done, then the sample solutions
were analyzed at max 222 nm by using double beam U.V/visible spectrophotometer (SHIMADZU-
1700) and dissolution medium as blank. Experiments were performed in triplicates. The amount of
drug present in the samples was calculated with the help of calibration curve constructed from
reference standard.
5.9 COMPARISON OF DISSOLUTION PROFILES41:
Difference factor (f1): Difference factor measures the percent error between two curves over all
time points. N
Rj and Tj are the percent dissolved of the reference and test products at each time point j. The
percent error is zero when the test and the reference profiles are identical and increases
proportionally with increasing dissimilarity between the two dissolution profiles.
Similarity Factor (f2): Similarity factor is a logarithmic reciprocal square root transformation of
one plus the mean squared (the average sum of squares) differences of drug percent dissolved
between the test and the reference products. According to FDA, the two dissolution profiles are
similar if f2 is between 50 and 100.
In general, f1values lower than 15 (0-15) and f2 values higher than 50 (50-100) indicate similarity of
dissolution profiles.
Drug release kinetics: (Brahmankar DM et al., 2005)( Costa P et al.,Pharm Sci 2001)
Zero order kinetics: Drug dissolution from pharmaceutical dosag forms that do not disaggregate
and release the drug slowly (assuming that area does not change and no equilibrium conditions are
obtained) can be represented by the following equation:
W0 Wt = K0t
Where W0 is the initial amount of drug in the pharmaceutical dosage form, Wt is the amount of drug
in the pharmaceutical dosage form at time t and k is proportionality constant. Dividing this equation
by W0 and simplifying:
ft= k0t
Where ft = 1 (Wt / W0 ) and ft represents the fraction of drug dissolved in time t and k0 the
apparent dissolution rate constant or zero order release constant in this way, a graphic of the drug-
dissolved fraction versus time will be linear if the previously established conditions were full filled.
In this way a graphical relationship between ft versus time to get the Zero order constant from the
slope. This relation can be used to describe the drug dissolution of several types of modified release
pharmaceutical dosage forms, as in the case of some transdermal systems as well as matrix tablets
with low soluble drugs (Varelas et al., 1995), coated forms, osmotic systems, etc. the pharmaceutical
dosage forms following this profile release the same amount of drug by unit of time and it is the ideal
method of drug release in order to achieve pharmacological prolonged action.
First order kinetics: This type of model to analyze drug dissolution study was first proposed by
Gibaldi and Feldman and later by Wagner. The relation expressing this model:
Log Qt = Log Q0 + K1t/2.303
Where Qt is the amount of drug released in time t, Q0 is initial amount of drug in the solution and
K1 is the first order release rate constant. In this way a graphical relationship between log percent
drug remaining versus time to get the First order constant from the slope. The pharmaceutical dosage
forms following this dissolution profile, such as those containing water-soluble drugs in porous
matrices release the drug in a way that is proportional to the amount of drug remaining in its interior,
in such a way, that the amount of drug released by unit of time diminishes.
Higuchi Model: (Higuchi 1961, Higuchi 1963, Cobby et al., 1973):
Qt = KHt1/2
Where,
Qt = the amount of drug released at time t and
KH = the Higuchi release rate;
This is the most widely used model to describe drug release from pharmaceutical matrices. A linear
relationship between the square root of time versus the concentration indicates that the drug release
follows strict Fickian diffusion. For purpose of data treatment, the above equation is usually reduced
to:
Q = Kt1/2
Therefore a plot of amount of drug released versus the square root of tim should be linear if drug
release from the matrix is diffusion controlled. Alternatively the drug release rate is proportional to
the reciprocal of the square root of time. An important advantage of the above equations is its
simplicity.
Korsmeyer Peppas model: (Korsmeyer et al., 1983, Peppas 1985 and Harland,1988): Korsmeyer et
al., (1983) developed a simple semi empirical model, relating exponentially the drug release to the
elapsed time (t).
Qt/Q = Kktn
Where Kk is a constant incorporating structural and geometric characteristic of the drug dosage form
and n is the release exponent, indicative of the drug release mechanism. For, an n value of ~0.5
indicates diffusion controlled mechanism while an n value of~1.0 indicates erosion (Ford et al.,
1991) Hariharan et al., 1997 a suggested that if the value of n is 0.5, it indicates Fickian transport, a
value of 0.5 and 1.0 non-Fickian transport, and the values close to 1.0 indicate that the system is
releasing drug in a zero order manner regardless of the actual mechanism of release.
Anomalous transport
0.89 Case-II transport Zero-order release
This type of analysis of release behavior is valuable is to the formulator for comparative purposes .
The Release exponent can be obtained from the slope and the Constant (Kk) obtained from the
intercept of the graphical relation between logarithmic versions of left side of the equation versus log
t.
RESULTS
6.1 PREFOMULATION STUDIES:
API evaluation:
a) Organoleptic evaluation:
Table No:17 Organoleptic properties of Glipizide
Properties Results
Description powder
Taste Tasteless
Odour Odourless
Colour Colourless
b) Solubility:
Glipizide practically insoluble in water and ethanol, soluble in chloroform, dimethylformamide, and
in dilute solution of alkali hydroxides, sparingly soluble in acetone.
Standard plot for Glipizide
Table No: 18 Calibration curve of Glipizide
2 (g/ml)
0.7 0.0420 0.0425 0.0422 0.0423
Fig No: 10 FTIR study for drug with Polyox WSR coagulant
The tablets of 7 formulations were tested and analysed for thickness, weigh variation, hardness,
friability, content uniformity.
Time(hr) Reference F1 F2 F3 F4 F5 F6 F7
F5 R2 value
0.973 R2 value
0.847 0.971 0.961 1.836
The drug release studies were analyzed for kinetics model to determine its order and mechanism of
drug release. The above table shows the data of formulations F1 to F7. From that all formulations F5
formulation is optimized based on the similarity factor. Figure no show the graphical representation
of order of kinetics of the optimized formulation.
DISCUSSION
6.5 PHYSICAL CHARACTERISTICS OF GLIPIZIDE:
1. Solubility: The solubility is higher in pH 7.5 PBS. It is (0.250mg/ml).
2. Melting Point: Melting point of Glipizide was determined by capillary tube method and it was
found to be 208.5C (n = 3). This value is same as that of the literature citation.
6.6 CALIBRATION CURVES OF GLIPIZIDE IN DIFFERENT MEDIA:
Standard Calibration curves of Glipizide in different media were plotted by tacking concentration
ranging from 2 to 12g/ml.
Standard calibration curve of Glipizide in PBS pH 7.5: The slope area value was found to be
0.0526 and the coefficient of correlation (r) was found to be 0.999. From the slope area and intercept
values it was found that the curve is having a positive slope and intercept. As the coefficient of
correlation value is 0.999 the values are acceptable.
6.7 FT-IR RESULTS:
FT-IR studies were carried out for pure drug alone and along with excipients. The pure drug FT-IR
spectrum -c=o, urea stretching wavenumber 1653 cm-1, Cyclohexyl stretching wavenumber 1157
cm-1, SO2NH stretching wavenumber 1331 cm CONH stretching wavenumber 1637 cm-1 observed.
Similarly FT-IR spectra of glipizide in combination with excipients are shown in Figures no9 to 10.
The peaks can be considered as characteristic peaks of glipizide. These peaks were not affected and
prominently observed in FT-IR spectra. This indicates that there is no interaction between glipizide
and excipients and the drug was compatible with the formulation components.
6.8 FLOW PROPERTIES OF POWDERED BLEND:
Push layer powder blend is having good flow properties, for this layer no need of granulation. The
flow properties values are mentioned below.
Bulk density: The bulk density for the entire tablet blends lies within the range of 0.388 to
0.431gm/cm3.
Tapped density: The tapped density for the entire tablet blends lies within the range of 0.431 to
0.470gm/cm3.
Carrs Index: The percentage compressibility or Carrs index for the entire tablet blends lies within
the range of 3.4% to 13.3%. This indicates that all the formulations had shown good in flow
properties.
DEPATRMENT OF INDUSTRIAL PHARMACY, NIPS Page 57
RESULTS AND DISSCUSION
Hausners ratio: The Hausners ratio for the entire tablet blends lies within the range of 1.03 to
1.153. This indicates that all the formulations had shown good in flow properties.
Angle of Repose: The angle of repose for the entire tablet blends lies within the range of 21to 26.0.
This indicates that all the formulations had shown excellent in flow properties.
6.9 EVALUATIONS OF ANTI-DIABETIC CONTROLLED POROSITY
OSMOTIC TABLETS:
Prepared tablets of Glipizide of all the formulations (F1 to F7) were round in shape with convex
surfaces. All the formulations were evaluated for thickness, drug content, weight variation, hardness
and friability.
Tablet appearance:
All the formulated Anti-diabetic osmatic tablets were evaluated for their appearance . The tablets had
white to cream white in colour.
Drug content:
All the formulated Anti-diabetic osmotic tablets were evaluated for their drug content and the results
had shown in table-20. The drug content of all the formulations was in the range 94.132.00% to
102.51.99%sec. These results suggested the drug content had found out within the limits i.e,
( 90.0% to 110.0%) according to USP.
Tablet thickness:
Tablets thickness is one of the important physical parameter as it may affect the uniformity and pose
different in packing and also affect the hardness of the tablet. All the formulated Bilayer push pull
Anti-diabetic osmatic tablets were evaluated for their thickness and the results had shown in table
no-20. The thickness of all the formulations was in the range of 4.64 0.12 to 4.71 0.04.
Tablet Weight variation:
Tablet weight variation is one of the important parameter as it may affect the content uniformity of
the tablet. All the formulated Anti-diabetic osmatic tablets were evaluated for their weight variation
and the results had shown in table no-20. The weight variation of all the formulations was in the
range of 195.6 2.33 to 210.7 3.73. The weight variation of the tablets was within the permissible
limit of 5.0%, as USP specified for tablet weight more than 206mg.
Tablet Hardness:
Tablet hardness is one of the important parameter as it may affect the friability and disintegration of
the tablet. All the formulated Anti-diabetic osmatic tablets were evaluated for their hardness and the
results had shown in table no.20. The hardness of all the formulations was in the range of 6 0.25
kp/cm2 to 8 0.23 kp/cm2, which was found to be acceptable.
Tablet Friability:
Tablet friability is one of the important parameter to evaluate the ability of the tablets to withstand
abrasion in packing, handling and transporting. All th formulated Anti-diabetic osmatic tablets were
evaluated for their friability and the results had shown in table no-20. The friability of all the
formulations was in the range of 0.1% to 0.5%, which was found to be within acceptable limit of
<1% as USP specified.
6.10 In-Vitro DISSOLUTION STUDY:
In-vitro dissolution studies were conducted for a period of 16 hours using USP dissolution apparatus
II (ELECTROLAB, Mumbai) at rpm of 50 and at a temperature of 37 0.50c and 900ml dissolution
medium of 7.5PBS.
The in vitro drug release of F2 formulation with 3% osmogent and coating ratio 70:30 was found to
be 38%
F3 formulation with 3% osmogent and coating ratio 50:50 was found to be 44%
F4 formulation with 5% osmogent and coating ratio 70:30 was found to be 48%
F5 formulation with 5% osmogent and coating ratio of 50:50 was found to be 94%.
F5 was found to be optimized formula as the concentration of osmogent (NaCl) increases,drug
release also increases and also as the concentration of pore former (PEG) increases, the number
of pores formed increases and drug release also increases.
In F5 formulation, there is increase in both pore former and osmogent.
F6 formulation with 7% osmogent and coating ratio of 70:30 was found to be 50%.
F7 formulation with 7% osmogent and coating ratio of 50:50 was found to be 39%.
Finally 3% coating buildup 5% sodium chloride and 50:50 ratio of cellulose acetate :polyethylene
glycol containing formulation F12 had maximum cumulative % Drug release was found to be 94%.
The stability studies were conducted for the optimised fomulation F5 for 3 months The stability
studies results concluded that the drug content deviation is with in the limits after 3 months duration
also.
6.16. STABILTY OF OPTIMISED FORMULATION F5:
Table.No.25: In vitro drug release data of the stability formulation F5
1 1 0 0 0 0
SUMMARY
The goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site in
the body and also to promptly achieve and maintain the desired drug concentration over entire period
of treatment.
Osmosis is one of the widely used methods for developing the new oral dosage forms to
control the drug release from the dosage form, improve the bioavailability, reduce adverse
effects especially drug with small therapeutic range and prolong the action of drug.
Glipizide is a potent antidiabetic agent used in the treatment of diabetes. It is insoluble in
water and ethanol, soluble in chloroform. The plasma half-life of glipizide is 1.5- 2 hours, has
short elimination half life of 2-3 hours.
In the present study seven formulations were formulated by using various concentrations of
sodium chloride and varying coating percentages of cellulose acetate and polyethylene glycol
400.
In-vitro study of formulations F2 , F3 and F4 showed slow release of drug. F6 and F7 had
shown faster drug release rate. F5 showed good controlled release profile.
F5 formulation with 1:5 (drug :osmogent ratio) and 50:50 (cellulose acetate : Polyethylene
glycol 400) was finalized as optimized formula
In-vitro release profile of formulation F5 was found to be similar to that of marketed
innovator product (Glucotrol XL).The f2values for the comparison of release of drug from
the formulation F4 with the marketed innovator product drug release profile were found to be
94%. Finally the F5 formulation was optimized.
CONCLUSION
The conclusions drawn from the present investigation are as follows.
Extended release formulations of Glipizide were developed based on controlled porosity
osmotic pump technology.
Core tablets of Glipizide were successfully prepared by wet granulation for drug layer using
Glipizide, sodium chloride,polyox WSR Cogulant , Magnesium stearate and ethanol used as a
granulating fluid. After compression core tablets coated with cellulose acetate as a
semipermiable membrane, PEG 400 as a plasticizer, acetone and water used as a solvents.
In vitro release profile of formulation F5 was found to be similar to that of marketed
innovator product (Glucotrol XL).The f2values for the comparison of release of drug from
the formulation F4 with the marketed innovator product drug release profile were found to be
94%. Finally the F5 formulation was optimized.
The effect of different formulation variable was studied to optimize release profile. The
release rate increased significantly as the increase of sodium chloride amount from 30mg to
70mg.
REFERENCES
1.Amir M. Razaghi, Joseph B. Schwartz, Release of Cyclobenzaprine Hydrochlorid from
OsmoticallyRupturable Tablets, Drug Development and Industrial Pharmacy, Volume 28, Number
6 / 2002, 695 701.
2. Brahma PG, NavneetT (2010), Osmotically Controlled Drug Delivery System with
AssociatedDrugs. J Pharm Pharmaceutical Sci; 13(3): 571-588
3. B Mishra, BK Makesh, C Sankar Oral push-pull osmotic pumps o pentazocinehydrochloride:
Development and evaluation Indian Journal o Pharmaceutical Sciences Year : 2006 Volume : 68
Issue : 1,: 85-87.
4. Chien YW. Novel drug delivery systems, Fundamentals, Development al concepts, biomedical
assessments. 1sted New York, Marcel Dekker INC 2001,pg.no.182.
5. Brahmankar DM, Jaiswal SB. Biopharmaceutics and pharmacokinetics a Treatise. 1st ed. Delhi:
VallabhPrakashan; 2005 pg. no335-350..
6. Chien YW. Novel drug delivery systems, Fundamentals, Development al concepts, biomedical
assessments. 1sted New York, Marcel Dekker INC 2001, pg.no. 201.
7. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles.EurJPharmSci 2001;13:123-
33.Pharm Sci 2001;13:123-33.
8. D. Prabakaran, Paramjit Singh, ParijatKanaujia, K.S. Jaganathan, AmitRawat, Suresh P. Vyas,
Modified pushpull osmotic system for simultaneous delivery of theophylline and salbutamol:
development and in vitro characterization , International Journal of Pharmaceutics 284 (2004) 95
108.
9. En-Xian Lu1, Zhi-Qiang Jiang, Qi-Zhi Zhang, Xin-Guo Jiang, A water insoluble drug monolithic
osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding agent, Journal
of Controlled Release 92 (2003) 375 382.
10. En-Xian Lu1, Zhi-Qiang Jiang, Qi-Zhi Zhang, Xin-Guo Jiang, A water insoluble drug
monolithic osmotic tablet system utilizing gum arabic as an osmotic, suspending and expanding
agent, Journal of Controlled Release 92 (2003) 375 382.
11. F. Theeuwes, Elementary osmotic pump, Journal of Pharmaceutical Sciences,(1975) vol. 64,
no. 12, pp. 19871991.
12. Lechman, L., Liberman, H.A., Kanig, J.L., In., The Theory and Practice of Industrial Pharmacy,
3 rd Ed., Varghese Publishing House, Bombay ,(1987), p 297